IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v8y2007i2p145-151.html
   My bibliography  Save this article

Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system

Author

Listed:
  • K. Le Lay
  • E. Myon
  • S. Hill
  • L. Riou-Franca
  • D. Scott
  • M. Sidhu
  • D. Dunlop
  • R. Launois

Abstract

No abstract is available for this item.

Suggested Citation

  • K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois, 2007. "Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 145-151, June.
  • Handle: RePEc:spr:eujhec:v:8:y:2007:i:2:p:145-151
    DOI: 10.1007/s10198-006-0034-1
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-006-0034-1
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s10198-006-0034-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Nicola J. Cooper & Keith R. Abrams & Alex J. Sutton & David Turner & Paul C. Lambert, 2003. "A Bayesian approach to Markov modelling in cost‐effectiveness analyses: application to taxane use in advanced breast cancer," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 166(3), pages 389-405, October.
    2. Douglas K. Miller & Sharon M. Homan, 1994. "Determining Transition Probabilities," Medical Decision Making, , vol. 14(1), pages 52-58, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Peter Bayer & Joel S. Brown & Johan Dubbeldam & Mark Broom, 2022. "A Markovian decision model of adaptive cancer treatment and quality of life," Post-Print hal-03767027, HAL.
    2. Philip Haywood & Johan Raad & Kees Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward, 2012. "Chemotherapy Administration," PharmacoEconomics, Springer, vol. 30(12), pages 1173-1186, December.
      • Philip Haywood & Johan Raad & Kees Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward, 2012. "Chemotherapy Administration," PharmacoEconomics, Springer, vol. 30(12), pages 1173-1186, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Thomas Hoffmann & Helmut Brunner, 2004. "Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 129-135, May.
    2. A. E. Ades & A. J. Sutton, 2006. "Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 169(1), pages 5-35, January.
    3. Jan Jürgensen & Robert Ikenberg & Roger-Axel Greiner & Volker Hösel, 2015. "Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 377-390, May.
    4. Peter Bayer & Joel Steven Brown & Johan Dubbeldam & Mark Broom, 2022. "A Markovian decision model of adaptive cancer treatment and quality of life," Working Papers hal-03542494, HAL.
    5. Rachael Fleurence & Christopher Hollenbeak, 2007. "Rates and Probabilities in Economic Modelling," PharmacoEconomics, Springer, vol. 25(1), pages 3-6, January.
    6. McClean, Sally & Gillespie, Jennifer & Garg, Lalit & Barton, Maria & Scotney, Bryan & Kullerton, Ken, 2014. "Using phase-type models to cost stroke patient care across health, social and community services," European Journal of Operational Research, Elsevier, vol. 236(1), pages 190-199.
    7. Hua Zhang & Mingdong Huo & Jianqian Chao & Pei Liu, 2016. "Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-9, August.
    8. Bonny Parkinson & Sallie-Anne Pearson & Rosalie Viney, 2014. "Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 93-112, January.
    9. Lartey, Stella T. & Si, Lei & Otahal, Petr & de Graaff, Barbara & Boateng, Godfred O. & Biritwum, Richard Berko & Minicuci, Nadia & Kowal, Paul & Magnussen, Costan G. & Palmer, Andrew J., 2020. "Annual transition probabilities of overweight and obesity in older adults: Evidence from World Health Organization Study on global AGEing and adult health," Social Science & Medicine, Elsevier, vol. 247(C).
    10. Francesco Saverio Mennini & Simone Russo & Andrea Marcellusi & Giuseppe Quintaliani & Denis Fouque, 2013. "Economic effects of treatment of chronic kidney disease with low-protein diet," CEIS Research Paper 292, Tor Vergata University, CEIS, revised 10 Oct 2013.
    11. Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
    12. Nicola J. Cooper & Alex J. Sutton & Keith R. Abrams & David Turner & Allan Wailoo, 2004. "Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 203-226, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:8:y:2007:i:2:p:145-151. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.